MASSDEVICE ON CALL — Diagnostics and stents maker Volcano (NSDQ:VOLC) may be primed for acquisition, with a raft of analysts’ groups debating only the timing of a buy.
Volcano’s stents and stent placement and evaluation technologies could draw buyers from some of medtech’s biggest players, such as Medtronic (NYSE:MDT) and Abbott (NYSE:ABT), according to market reports.
Engaged Capital, which owns a significant stake in the company, recommended patience, saying the company may garner a higher price if it waits to sell. Analysts for Eagle Asset Mgmt. recommended that buyers jump now while stock prices are still under pressure from a sluggish stent market, Bloomberg reported.
San Diego, Calif.-based Volcano revealed in earlier this month that Engaged Capital purchased some 5.1% shares of VOLC stock and began demanding changes at the company, including revisions to management compensation packages, a $200 million share buyback and calling for the company to resist acquiring any more companies to focus solely on "organic growth."
Abbott donates $450k in grants, medical products to storm-ravaged Philippines
Healthcare giant Abbott (NYSE:ABT) donated $350,000 in grants and $100,000 in drugs and other medical products to relief efforts in the areas ravaged by Typhoon Haiyan.
Read more
About 1 million signed up for Obamacare so far
Nearly 1 million patients have completed the sign-up process for state and federal health insurance exchanges, and more than 100,000 have selected plans.
Read more
Online healthcare riddled with security risks, project manager says
Healthcare.gov chief project manager Henry Chao told Congress that the online insurance exchange system is full of security gaps that could lead to "limitless" risks to security and privacy.
Read more
Titan Spine implants 18,000th device
Wisconsin medical device maker Titan Spine celebrates the 18,000th implant of its Endoskeleton interbody fusion system, designed to promote bone growth and spur "faster and more robust fusion."
Read more